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Small heat shock protein 20 (Hsp20) facilitates
nuclear import of protein kinase D 1 (PKD1)
during cardiac hypertrophy
Yuan Yan Sin1, Tamara P Martin1, Lauren Wills1, Susan Currie2 and George S Baillie1*
Abstract
Background: Nuclear import of protein kinase D1 (PKD1) is an important event in the transcriptional regulation of
cardiac gene reprogramming leading to the hypertrophic growth response, however, little is known about the
molecular events that govern this event. We have identified a novel complex between PKD1 and a heat shock
protein (Hsp), Hsp20, which has been implicated as cardioprotective. This study aims to characterize the role of the
complex in PKD1-mediated myocardial regulatory mechanisms that depend on PKD1 nuclear translocation.
Results: In mapping the Hsp20 binding sites on PKD1 within its catalytic unit using peptide array analysis, we were
able to develop a cell-permeable peptide that disrupts the Hsp20-PKD1 complex. We use this peptide to show that
formation of the Hsp20-PKD1 complex is essential for PKD1 nuclear translocation, signaling mechanisms leading to
hypertrophy, activation of the fetal gene programme and pathological cardiac remodeling leading to cardiac fibrosis.
Conclusions: These results identify a new signaling complex that is pivotal to pathological remodelling of the heart
that could be targeted therapeutically.
Keywords: Hsp20, PKD1, Cardiac hypertrophy, Peptide array
Introduction
Cardiac myocytes respond to pathological stress via
activation of the fetal gene programme (reviewed in [1]).
Essential to this process, is the activation of cardiac
protein kinase D (PKD). PKD1 is a ubiquitously expressed
serine/threonine kinase and is the most characterised
member of a kinase family within the CaMK group
(comprising PKD1, PKD2, and PKD3) of kinases [2]. In
the adult heart, PKD1 is activated in response to chronic
adrenergic signalling, hypertension and pressure overload.
Phosphorylation and hence activation of PKD1 occurs
initially via binding to diacylglycerol [3] at its cystein-rich
domain with kinase activation/translocation being triggered
by PKC-phosphorylation and the release of pleckstrin
homology (PH)-mediated PKD1 inhibition [4]. Upon cell
stimulation, PKD isoforms translocate from the cytosol to
DAG-containing microenvironments at the plasma mem-
brane and then back to the cytosol and into the nucleus [5].
PKD has been implicated in a variety of cellular responses
including cell proliferation, inflammation, cardiac
contractility and hypertrophy [2]. In the heart, PKD1
has been shown to regulate myofilament function and Ca2+
sensitivity by phosphorylating cardiac troponin I [6,7].
PKD1 also regulates cardiac myocyte hypertrophy by
translocating into the nucleus and directly phosphorylating
class II histone deacetylase 5 (HDAC5) [8]. HDACs deace-
tylate histones resulting in transcriptional repression.
HDAC phosphorylation, for example by PKD1 and
CaMKII [9], creates docking sites for 14-3-3 chaperone
proteins that escorts them from the nucleus to the
cytoplasm, thus relieving downstream transcription
factors (such as myocyte enhancer factor-2 (MEF2)), of
their repression [10,11]. However, little is known about the
molecular events that govern PKD1 nuclear translocation.
In a proteomics screen to discover novel partners for the
chaperone heat shock protein 20 (Hsp20), we found PKD1
to be a robust Hsp20-binding protein. Hsp20 (reviewed
in [12]) displays cardioprotective actions including
anti-ischaemic, anti-apoptotic and anti-hypertrophic effects.
At basal level, HSP20 is primarily found in the cytosol but a
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subpopulation may translocate into the nuclear compart-
ment in response to stress signals [13].
In this manuscript, we verify the interaction between
Hsp20 and PKD1 and use novel peptide disruptors to
show firstly, that formation of the Hsp20-PKD1 complex
is required for hypertrophic signaling, secondly, that
Hsp20 facilitates the nucleo-cytoplasmic shuttling of
PKD1 and thirdly, that the Hsp20-PKD1 interaction pro-
motes stress related left ventricular (LV) dysfunction and
cardiac fibrosis.
Results and discussion
Hsp20 and PKD1 form a complex in cardiac myocytes
The protective functions of Hsp20 in a cardiac setting have
received much attention and in an attempt to elucidate
the molecular mechanisms involved, we endeavored to
characterise putative interactors of Hsp20 using high-
density ProtoArray Human Protein Microarray (Invitrogen,
UK) analysis. Using this method, a previously unknown
Hsp20-binder was identified as PKD1 (Figure 1A).
The interaction was verified by pull-down analysis of
recombinant proteins (Figure 1B) and immunoprecipitation
of exogenously (Figure 1C) and endogenously (Figure 1D)
expressed cardiac myocyte proteins. Co-localisation immu-
nostaining (Figure 1F) demonstrated positive correl-
ation in HEK293 cells overexpressing Hsp20 and
PKD1 (Pearson’s 0.62 ± 0.03, Manders’ 0.81 ± 0.02, M1
0.96 ± 0.01, M2 0.95 ± 0.01) and in myocytes expressing
endogenous Hsp20 and PKD1 (Pearson’s 0.81 ± 0.02,
Manders’ 0.88 ± 0.01, M1 0.86 ± 0.03, M2 0.93 ± 0.01).
This data suggests that Hsp20 and PKD1 locate to the
same region of cells. Peptide array technology was also
utilized, where the sequence of PKD1 was spotted in
25mer peptides, each shifted by five amino acids [14]. As
shown in Figure 1E, Hsp20 interacted directly with PKD1,
and the interaction site was mapped to a 25mer sequence
spanning residues 606 to 630 within the PKD1 catalytic
unit. Subsequent alanine scanning peptide array, whereby
every amino acid was replaced sequentially with alanine,
pinpointed the residues on PKD1 that are essential for
interaction as R607, D608, V609, I611, I613, D615, E624
(Figure 1E lowest panel).
The Hsp20-PKD1 complex is required for
hypertrophic signaling
As both PKD1 and Hsp20 are strongly implicated in
hypertrophic signaling [11,13,15], we decided to probe
the functionality of the complex by using cell-permeable
peptides, designed using the information gleaned
from peptide array analysis (Figure 1E), to disrupt
the Hsp20-PKD1 interaction. Previous work from our
group has shown that cell-permeable analogues of
25mer peptides identified in this manner, often can be
used to disrupt signalling complexes, thereby effecting
specific cardiovascular-specific functional outputs such as
phosphorylation of the β2-adrenergic receptor by PKA
[16], recruitment of EPAC to the β 2-adrenergic receptor
[17], permeability of the vascular epithelium [18] and
tubule formation by human arterial endothelial cells [19].
Indeed, we have already used this approach successfully to
disrupt another Hsp20 binding partner, PDE4D5, in order
to induce cardioprotection [15].
Gratifyingly, a disruptor peptide comprising of PKD1
residues 606 to 630 (DIS), but not a control peptide
(CTR) with three of the seven key residues replaced by
alanine (GAAVAIKIIAKLRFPTKQESQLRNE), ablated
co-immunopreciptation of endogenous Hsp20 and PKD1
from neonatal cardiac myocyte lysates (Figure 2A). As we
could successfully disrupt the Hsp20-PKD1 complex with
disruptor peptide (Figure 2A), we were interested to see if it
would be able to attenuate the hypertrophic response
induced by chronic β-agonist (isoprenaline; ISO) stimula-
tion of neonatal cardiac myocytes. To this end, we utilised
3 different assay methods to measure the effectiveness
of the peptide to confer protection against β-adrenergic
receptor-triggered hypertrophic signalling. Firstly, we
employed a novel approach utilizing xCELLigence
technology, which we have previously developed [15]
to measure the size of cardiac myocytes (Figure 2B
and C). Secondly, we measured the relative protein/DNA
ratio of cells (Figure 2D) and thirdly, in order to investigate
whether the peptide affected increased fetal gene expression
that characterises the hypertrophic response, we deter-
mined the mRNA levels of 3 hypertrophy marker genes
atrial naturietic peptide (ANP), brain naturietic peptide
(BNP) and β-myosin heavy chain (β-MHC) (Figure 2E). All
three techniques suggested that the disruptor peptide
(but not control peptide) could attenuate the hypertrophic
response. Note that differences seen in BNP between ISO
and ISO plus control peptide are not significant (p = 0.46)
Cell size, measured in real-time by cell index (CI; Figure 2B
and C) and protein/DNA ratio (Figure 2D) of cells
increased following chronic ISO treatment and were
significantly reduced by pre-treatment with disruptor
peptide but not with control peptide. The Hsp20-PKD1
disruptor peptide also significantly reduced the upregula-
tion of fetal gene expression (Figure 2E) triggered by
chronic β-agonist stimulation. Another key characteristic
of hypertrophy is the reorganization of actin filaments
[20] and we were able to observe the expected formation
of β-adrenergic–stimulated stress fibers when compared
with untreated cells (Figure 2F). Interestingly, the actin
cytoskeletal rearrangement stimulated by hypertrophy
induction was visibly reduced in cells pre-treated with
disruptor peptide, but not control peptide, (Figure 2F)
suggesting that the Hsp20-PKD1 association is also
likely to have the capacity to regulate the integrity of
cellular actin filaments.
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Hsp20 acts as a nuclear import chaperone
for PKD1
In normal functioning cardiac myocytes, the majority of
PKD1 localises to the cytosol, while a subpopulation is
found in various organelles, such as the nucleus, plasma
membrane, mitochondria and trans Golgi network [21].
PKD1 is bound by DAG at its cystein-rich domain
and kinase activation/translocation is triggered by
PKC-phosphorylation and the release of PH-mediated
PKD1 inhibition [5]. This chain of molecular events
promotes PKD1 activation, and it has been established that
PKD1 undergoes nuclear shuttling to initiate gene tran-
scription following chronic β-adrenergic -agonist stimula-
tion [8]. However, little is known about the molecular
events that underpin PKD1 nuclear translocation. A-kinase
anchoring protein (AKAP-Lbc), a protein that is known
to bind PKD1 [22] and Hsp20 [23], can coordinate and
activate movement of signaling proteins that initiate
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Figure 1 PKD1 and Hsp20 form a signaling complex in cardiac myocytes. A. ProtoArray Human Protein Microarray screen identified PKD1 as
an interacting partner for Hsp20 (top panel, compared to control, bottom panel). B. In vitro pull-down assay showed that recombinant His-Hsp20,
but not control His-tag, co-purifies with PKD1. C. Overexpressed Hsp20-V5 and GFP-PKD1 co-immunoprecipitate when expressed in HEK293 cells.
D. Endogenous Hsp20 and PKD1 from cardiac myocyte lysate co-immunoprecipitate. Mock IP represents respective IgG only. Data representative
of n = 3 independent experiments. E. Peptide array analysis identifies Hsp20 binding site within the catalytic domain of PKD1 (G606-E630). F. Overexpressed
Hsp20-V5 and GFP-PKD1 co-localise in HEK293 cells and endogenous Hsp20 and PKD1 co-localise in cardiac myocytes. Pearson’s coefficient for Hsp20
and PKD1 is shown along with Manders’ coefficients (M1 and M2), which represent the fraction of the Hsp20 red overlapping with PKD1 green and the
fraction of PKD1 green overlapping with the Hsp20 red, respectively. The results are shown as means ± SEM of several images where at least 10 individual
cells were analysed for each coefficient.
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MEF2-mediated transcription, however, the AKAP
does not directly facilitate nuclear entry of PKD1 as
the scaffold does not change localization following
agonist stimulation. To investigate a possible role for
Hsp20 in the nuclear influx of PKD1, we used a novel
in situ proximity ligation assay (PLA) to allow high
resolution of the distribution of the Hsp20-PKD1
complex (Figure 3). Under basal, unstimulated conditions,
diffuse cytoplasmic staining of Hsp20-PKD1 complexes
were observed suggesting that the Hsp20-PKD1 complex
was excluded from the nucleus (Figure 3A). In contrast,
Hsp20-PKD1 complexes were significantly enriched, with
increased localization to the nuclei of ISO-treated cardiac
myocytes (Figure 3A and B). A similar distribution
pattern was also observed in cells treated with control
peptide + ISO. However, treatment of the cells with
disruptor peptide triggered a significant change in the
intracellular localisation of Hsp20-PKD1 complexes.
When the interaction between the two proteins was
perturbed, significantly less Hsp20-PKD1 complex was
visible globally and complexes that were observed
showed little nuclear localization (Figure 3A and B).
To support findings from the PLA assays and evaluate the
degree of Hsp20-PKD1 complex distribution, we resorted
to conventional cell fractionation (Figure 3C). In agree-
ment with data from PLA experiments, ISO treatment
triggered translocation of both PKD1 and Hsp20 to the
nucleus that could be attenuated with the disruptor
peptide but not with control (Figure 3D and E). PKD1
nuclear translocation during hypertrophic stimulus has
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Figure 2 Disruption of the Hsp20-PKD1 complex attenuates hypertrophic signaling in neonatal cardiac myocytes. A. A cell permeable
disruptor peptide (DIS), but not scrambled control (CTR), ablates interaction of PKD1 and Hsp20 in cardiac myocytes. B. and C. The Hsp20-PKD1
disruptor peptide reduces cardiac myocyte cell size following chronic β-adrenergic (isoprenaline; ISO) stimulation. D. The Hsp20-PKD1 disruptor
peptide reduces relative protein/DNA ratio of cells following chronic β-adrenergic stimulation (n = 9). E. The Hsp20-PKD1 disruptor peptide
reduces the expression of hypertrophic markers atrial natruiretic peptide (ANP), brain natruiretic peptide (BNP) and β-myosin heavy chain
(β-MHC) following chronic β-adrenergic stimulation (n = 7). F. The Hsp20-PKD1 disruptor peptide reduces actin cytoskeletal rearrangement
following chronic β-adrenergic stimulation. Data representative of n = 3 independent experiments.
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been characterised previously by others [22,24,25] however,
this is the first indication that the said nuclear import of
PKD1 is directly mediated by another protein (in this
case Hsp20).
The Hsp20-PKD1 complex directs cardiac
hypertrophy and cardiac fibrosis in vivo
Studies utilizing mice that have a cardiac-specific deletion
of PKD1 [26] showed that PKD1 acts as a key element of
the stress-stimulated signaling pathway involved in patho-
logical cardiac remodeling. One crucial component of
cardiac remodeling, contributing to compromised dia-
stolic function, is cardiac fibrosis. Interestingly, these mice
showed not only diminished cardiac myocyte hypertrophy
but also significantly reduced cardiac fibrosis. This added
to previous indirect evidence suggesting that PKD1 has a
role in controlling cardiac fibrosis [27,28].
To this end, we used a minimally invasive transverse
aortic banding (MTAB) model of pressure overload
induced cardiac hypertrophy [29] and compared them
to sham-operated mice following treatment with the
Hsp20-PKD1 disruptor and control peptides. Treatment
with disruptor peptide, but not control, prevented
MTAB-induced decreases in left ventricular contractility
(Figure 4; % fractional shortening: 44.0 ± 1.0% cf. 29.5 ±
4.0%, p < 0.0001, MTAB+DIS PKD and MTAB+CTR PKD,
respectively). Analysis of picrosirius red stained heart
sections from mice treated with control peptide showed
significantly increased collagen deposition (fibrosis) in
MTABmice compared with sham-operated mice (Figure 5;
16.3 ± 2.8% (MTAB+CTR PKD) cf. 8.1 ± 0.5% (sham+CTR
PKD), p < 0.01). In contrast, hearts from MTAB mice
treated with the Hsp20-PKD1 disruptor showed signifi-
cantly reduced fibrosis when compared with MTAB
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Figure 3 Hsp20 may act as a nuclear chaperone for PKD1. A and B. A novel proximity ligation assay was used to visualize and quantify PKD1
nuclear entry in neonatal cardiac myocytes. Images are shown as maximum projections of z-stacks of confocal images. PLA signals indicating
Hsp20-PKD1 complex formation were quantified using the analyse particles plugin of ImageJ software. For all experiments, quantifications were
performed from at least 12 images and expressed as mean number of signals per cell. C, D and E. Cell fractionation techniques were used to
visualize and quantify the cellular distribution profile of PKD1 and Hsp20 from cardiac myocytes. The disruptor peptide (PKD DIS) prevented ISO-induced
nuclear translocation of Hsp20-PKD1 complexes, compared to control peptide (CTR PKD). Data representative of n = 3 independent experiments.
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mice treated with control peptide (Figure 5; 5.2 ±
1.5% (MTAB+PKD DIS) cf. 16.3 ± 2.8% (MTAB control)
p < 0.001). This data suggests that interdiction of the
Hsp20-PKD1 complex is protective against accumulation
of fibrillar collagen and development of the cardiac
fibrosis that accompanies hypertrophic remodelling
following pressure overload.
Conclusions
In summary, we have discovered a novel protein complex
(Hsp20-PKD1) that appears to orchestrate hypertrophy
signalling pathways involved in the induction of fetal
gene program, pathological cardiac growth and cardiac
remodeling. As disruption of the complex significantly
retards these processes, we propose, the Hsp20-PKD1
signalling axis as a promising therapeutic target to
hinder the hypertrophic phenotype. Development of
Hsp20-PKD1 disruptors to prevent PKD1 nuclear trans-
location represents a novel route for the development of
anti-hypertrophic and anti-fibrotic agents.
Methods
Peptides
Hsp20-PKD1disruptor (GRDVAIKIIDKLRFPTKQESQL
RNE) and control peptide (GAAVAIKIIAKLRFPTKQ
ESQLRNE) were synthesised by GenScript and included
an N-terminal stearoyl group (CH3(CH2)16COOH)
making them cell permeable. For cell studies peptides
were dissolved in DMSO to a stock concentration of
10 mM and used at a final concentration of 10 μM,
B
A
Figure 4 Preserved cardiac function following Hsp20-PKD1 disruption. Mice undergoing sham or MTAB surgery were treated with 10 mg/kg
PKD-disruptor (PKD DIS) or a scrambled control (CTR PKD) peptide twice weekly for 4 weeks. A. Representative LV echocardiography M-mode
traces; AW, anterior wall; PW, posterior; EDD, end diastolic diameter; ESD, end systolic diameter. B. Histogram of average ± S.E.M fractional
shortening data, n ≥ 5 mice, *p < 0.05, ***p < 0.001, one-way ANOVA tests followed by post-hoc Tukey’s test.
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and for in vivo studies were dissolved in sterile saline
to 1 mg/ml.
Antibodies
Anti-His (H1029), anti-V5 antibodies (V8137) and anti-
Actinin (A7811) were from Sigma. Anti-HSP20 antibody
was from Millipore (07–490). Anti-GFP (ab290), anti-
phospho-HSP20 (ab58522), anti-HSP90 (ab13495) and
anti-GM130 (ab52649) antibodies were from Abcam.
Anti-PKD1 (sc-639) and anti-Lamin A/C (sc-56140) anti-
bodies were from Santa Cruz. Anti-PKD1 (H00005587-
A01) for immunostaining was from Abnova.
Cell culture, transfection, Western blotting and
immunoprecipitation
Neonatal rat cardiac myocytes were cultured as described
before [30]. For hypertrophy induction, cells were cultured
in serum-free medium for 48 h prior to stimulation by
10 μM of ISO for 24 h and where appropriate, cardiac
myocytes were pretreated with compounds. DNA plasmid
constructs used for transfection included V5-HSP20 in
pDEST vector and GFP-PKD1 in pEF-BOS vector. HEK
293 cells were transiently transfected with both plasmid
DNA using Polyfect Transfection Reagent (Qiagen)
following the manufacturer’s instruction. Cellular lysates
were prepared in lysis buffer [25 mM Hepes, 2.5 mM
EDTA, 50 mM NaC1, 50 mM NaF, 30 mM sodium pyro-
phosphate, 10% (v/v) glycerol, 1% (v/v) Triton X-100,
pH 7.5, containing Complete™ EDTA-free protease inhibitor
cocktail tablets (Roche)] after specified treatments. Protein
concentration of lysates was determined using the Bradford
assay and all samples were equalised for protein concentra-
tion. Proteins were separated by SDS/PAGE (4–12% Bis-
Tris gels) and transferred onto nitrocellulose membranes
for Western blotting. For immunoprecipitation, HSP20 or
PKD1 and V5 or GFP antibodies were used to immunopre-
cipitate endogenous, and over-expressed PKD1 and HSP20,
respectively. The resulting immunocomplexes were cap-
tured using Protein A beads (Invitrogen) at 4°C overnight
with shaking. The immunocomplexes were then collected
by centrifugation at 10 000 × g for 3 min and washed three
times with 3T3 lysis buffer. Bound proteins were then
Figure 5 Cardiac fibrosis is attenuated by disruption of Hsp20-PKD1 interaction. A. Picrosirius red staining of sham and MTAB hearts
following treatment of mice with 10 mg/kg PKD-disruptor (PKD DIS) or scrambled control (CTR PKD) peptide twice weekly for 4 weeks. B.
Histogram values represent stained area expressed as a percentage of the total area of interest. Data represents mean ± S.E.M., n≥ 3 mice,
**p <0.01, ***p < 0.001, ns p > 0.05, one-way ANOVA tests followed by post hoc Tukey’s tests.
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eluted in SDS-PAGE sample buffer and subjected to
SDS-PAGE and immunoblotting. Negative controls
using isotype-matched IgG (Jackson ImmunoResearch
Laboratories, Inc.) from the same species as the antibodies
were included to screen for non-specific binding.
Immunoreactive proteins were detected using horseradish
peroxidase-conjugated goat anti-rabbit or anti-mouse
secondary antibody (1:5000, Sigma-Aldrich) and visualized
by enhanced chemiluminescence detection (Pierce).
Quantification of the band intensity was accomplished by
densitometry using Quantity One 1-D software (Bio-Rad).
ProtoArray
To prepare the probe for ProtoArray analysis, Ultimate™
ORF clone IOH57317 (Invitrogen), containing the open
reading frame (ORF) of HSP20 in pENTR221 vector,
was used to generate N-terminal His-fusion protein
by Gateway cloning technology into pDEST-17 vector
(Invitrogen). The His-tagged HSP20 protein was
expressed in E.coli and purified by Ni-NTA Superflow
resin (Qiagen). Coomassie Blue staining and Western
blot with mouse monoclonal anti-His antibody (Sigma) and
rabbit polyclonal anti-HSP20 antibody (Upstate-Millipore)
verified the purity and specificity of the probes. Briefly, the
array was incubated in blocking buffer (1×PBS, 1% BSA
and 0.1% Tween 20) for 1 h at 4°C with gentle shaking to
block non-specific binding. The array was then probed with
10 μM (200 μg/ml) of His-HSP20 protein in probing buffer
(1×PBS, 5 mM MgCl2, 0.5 mM dithiothreitol (DTT), 0.05%
Triton X-100, 5% glycerol, 1% BSA) for 1.5 h at 4°C. After
washing, the array was incubated at 4°C with mouse
monoclonal anti-His antibody (Sigma) and Alexa Fluor
647 goat anti-mouse IgG (H + L) (Molecular Probes,
Invitrogen) diluted 1:2000 in probing buffer for 45 min
and 30 min, respectively. After washing and drying, the
array was scanned by ScanArray Express Microarray
Scanner (Packard Bioscience Biochip Technology,
PerkinElmer) at a wavelength of 633 nm. The results
were analysed using BlueFuse for Microarrays software
(BlueGnome, Cambridge), following acquisition of the
ProtoArray Lot Specific information. The Confidence Flags
were used to indicate the degree of confidence showing
potential interactions. A control array was also included in
parallel to determine probe-specific interactions and
exclude any non-specific interactions.
In vitro pull-down assay
Equal molar concentrations of purified recombinant His
(negative control) or His-HSP20 and PKD1 (Abcam)
were mixed in 3T3 lysis buffer and incubated end-on-end
with gentle agitation for 1 hour at 4°C. Pre-equilibrated
Ni-NTA Superflow resin (Qiagen) was then added to
the protein cocktail and incubated with gentle agitation
for another hour at 4°C. Beads were then sedimented by
centrifugation at 10,000 × g for 3 min, followed by
washing thrice with 3T3 lysis buffer. Proteins were
then resolved by SDS-PAGE with PKD1 protein run
alongside as a positive control, following by immuno-
blotting using an anti-PKD1 antibody.
SPOT synthesis of peptides and overlay experiments
This was done as described by us in detail elsewhere
[31].
Immunostaining and phalloidin staining of actin
For immunofluorescent labeling, cardiac myocytes were
plated onto laminin-coated 8-well chamber slides
(Lab-Tek, Sigma). Cells were fixed in 95% ice-cold
methanol/ 5% acetone mixture at −20°C for 10 min
and permeabilised with 0.1% Triton X-100 in PBS for
10 min at room temperature. After several washes
with Tris-buffered saline (TBS) (150 mM NaCl,
20 mM Tris–HCl, pH 7.6), the cells were blocked
with 10% donkey serum and 2% BSA (w/v) in TBS for 2 h
followed by three washes with TBS. The primary
antibodies used was diluted to the required concen-
tration in blocking buffer diluted 1:1 with TBS and
added to the cells for 2 h followed by three washes
with TBS. After washing, cells were incubated with
1:400 diluted secondary antibodies Alexa Fluor 488
donkey anti-mouse IgG and Alexa Fluor 594 donkey
anti-rabbit IgG (Molecular Probes) for 1 h. For phalloidin
staining, actin fibers were stained with Alexa Fluor 488
phalloidin (Molecular Probes, Invitrogen) diluted 1:500 in
PBS for 30 min at room temperature and washed thrice in
PBS. DAPI (Invitrogen) was used for nuclear counterstain.
Staining was visualised using a Zeiss Pascal laser-scanning
confocal microscope (LSM) 510 Meta and an Axiovert
100 microscope (Carl Zeiss, UK) equipped with an oil
immersion objective (63×/1.4 NA plan apochromat lens).
Single-plane images were captured at the same depth and
processed on Zeiss LSM Image Examiner. For quantitative
colocalisation analysis, Pearson’s (Rr), Manders’ overlap
(R) and colocalisation coefficients (M1, M2) were calcu-
lated for at least 10 individual cells selected randomly
using the ImageJ JACoP plugin (http://rsb.info.nih.gov/ij/
plugins/track/jacop.html). M1 signifies the correlation of
Hsp20 overlapping PKD1, while M2 indicates the overlap
coefficient of PKD1 to HSP20. A background correction
was performed prior to analysis to eliminate system
variability in the image background.
Real-time xCELLigence measurements
Cellular size of cardiac mycytes using xCELLigence
technology was carried out as described previously [15].
An initial population of 40,000 cardiac myocytes/well was
plated out on the laminin (BD Biosciences) pre-coated
E-Plate 96 (Roche) in triplicates after background
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measurements were taken. Briefly after 48 h of culture in
the serum-free medium, cardiac myocytes were treated
with either 10 μM ISO alone or ISO following a 30 min or
2 h pre-treatment with peptides. Controls with vehicle
(DMSO alone) were also performed. The cultures were
continuously monitored for up to 48 h and the impedance
as reflected by cell index (CI) values was set to record
every 30 min. The xCELLigence data were then analysed
using the RTCA software (Roche Applied Science). The
results were expressed by normalized CI, which are
derived from the ratio of CIs before and after the
addition of compounds.
Measurement of protein content
Cardiac myocytes were plated on six-well plates and
cultured in a serum-free condition for 48 h before
experiments. After stimulation of cardiac myocytes
(2 h of compound + 24 h of ISO or 24 h of ISO alone),
each well was rinsed three times with cold PBS. The cells
were then scraped with 1 ml of 1× standard sodium citrate
(SSC) containing 0.25% (w/v) SDS and vortexed exten-
sively. The total cell protein and the DNA content were
determined according to the manufacturers’ instructions
using Total Protein Kit (Sigma #TP0200) and DNA
Quantitation Kit (Sigma #DNA-QF), respectively. The
protein content was normalised by the DNA amount
to correct for differences in the cell number.
Quantitative real-time PCR analysis of fetal gene
expression
Total RNA of each condition was extracted using a TRIzol
reagent (Invitrogen) and purified with the RNeasy Mini Kit
(Qiagen). One microgram of DNase-digested total RNA
was reverse-transcribed to first strand complementary
DNA (cDNA) using AffinityScript Multiple Temperature
cDNA synthesis kit (Agilent, Edinburgh, UK) according to
manufacturer’s instructions. Real-time PCR primer-probe
sets (Eurofins MWG operon) were design assisted by the
Primer 3 software. Primer-probe sets were as follows:
Atrial natriuretic peptide (ANP): 5′-AGGCTGCAAC
AGCTTCCGGT-3′ (probe), 5′-GGATTGGAGCCCAGA
GCGGAC-3′ (sense), 5′-CGCAAGGGCTTGGGATCTT
TTGC-3″ (antisense); Brain natriuretic peptide (BNF):
5′-GCTGCTGGAGCTGATAAGAGAAAAGT-3′ (probe),
5′-AGCCAGTCTCCAGAACAATCCACG-3′ (sense), 5′-
AGGGCCTTGGTCCTTTGAGAGC-3′ (antisense); β-
myosin heavy chain (β-MHC): 5′- CTGGATGAGGCAGA
GGAGAG-3′ (probe), 5′-CCAACACCAACCTGTCCAA-3′
(sense), 5′-CAGCTTGTTGACCTGGGACT-3′ (antisense)
and rat 18S rRNA: 5′- TGAGGCCATGATTAAGAGGG-3′
(probe), 5′-CGCGGTTCTATTTTGTTGGT-3′ (sense),
5′-CGGTCCAAGAATTTCACCTC-3′ (antisense). Rat 18S
rRNA was used as an internal control for normalis-
ing relative expression levels in the different samples.
Real-time PCR reactions were prepared using Platinum®
Quantitative PCR SuperMix UDG with ROX (Invitrogen)
and performed in a 7300 Real time PCR System (Applied
Biosystems). Each PCR amplification was run in triplicate
using the following conditions: 2 min at 95°C, followed by a
total of 40 cycles (15 s at 95°C and 1 min at 60°C). Relative
gene expression was calculated using the comparative
threshold method (2-∆∆Ct) and is presented as fold change
of transcripts for gene of interest compared to 18 s rRNA.
Duolink™ proximity ligation assay
PKD1 association with HSP20 was investigated further
by using the Duolink™ Proximity Ligation Assay (PLA)
(Olink Bioscience, Uppsala, Sweden). After fixation,
permeabilisation and blocking, slides were incubated
with primary antibodies against PKD1 and HSP20 raised
in two different species. Then PLA probes, which are
conjugated with oligonucleotides, were introduced to
recognise the primary antibodies. A solution that pro-
motes hybridization between the PLA oligos was then
added, where a hybridisation reaction only occurred if
the two proteins were in close proximity (<40 nm), but
not if they were far apart. This reaction was followed by
ligation of the oligonucleotides and a rolling circle amp-
lification (RCA) reaction, where a repeated sequence
product was made. This product was then detected
using fluorescently labeled oligonucleotides, where a
Hsp20-PKD1association appeared as discrete red dots
under the microscope. Cells were counterstained with
α-actinin to show sarcomeric stained. Slides were finally
mounted under coverslips with DUOLINK mounting
media and visualised. In order to detect all PLA signals, a
series of Z-stack images was collected.
Subcellular fractionation of cardiac myocytes
Cardiac myocytes were fractionated into cytosolic, mem-
brane and nuclear fractions using FractionPrepTM
(BioVision, Mountain View, CA) following the manu-
facturer’s protocol. Equal amounts of each cell lysate
were used for Western blot analysis. To assess the
purity of fractionation, cytoplasmic, membrane and
nuclear fractions were confirmed by immunoblotting
using anti-HSP90 as cytoplasmic marker, anti-GM130
as membrane marker and anti-Lamin A/C as nuclear
marker, respectively.
Minimally invasive transverse aortic banding and
transthoracic echocardiography
Healthy adult male C57BL/6 J mice (Harlan, UK)
weighing between 25-30 g were used for these experiments.
Procedures conformed to the UK Animals (Scientific
Procedures) Act 1986 and were approved by institutional
ethical review committees. MTAB and sham surgical
protocols were performed as previously described [29].
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Immediately following surgery, animals were injected (in-
traperitoneal) with either Hsp20-PKD1disruptor peptide or
a scrambled control peptide at 10 mg/kg twice weekly and
were left for 4 weeks to allow cardiac remodeling to occur.
Echocardiographic assessment of left ventricular (LV)
function was performed 4 weeks after MTAB or sham
surgery, as described previously [29]. LV end systolic
dimension (LVESD) and LV end diastolic dimension
(LVEDD) were assessed from M-mode traces and %
fractional shortening calculated. Fractional shortening
(FS) is expressed as [(LVEDD-LVESD)/LVEDD] ×100.
An average of three measurements of each variable
per animal was used.
Picrosirius red staining
Four weeks post-surgery, animals were euthanized
with an intravenous injection of pentobarbital sodium
(Euthatal, 200 mg/kg). Terminal anaesthesia was con-
firmed by testing loss of the pedal reflex. Hearts were
rapidly excised and washed thoroughly in ice-cold
Ca2+-free Krebs solution (120 mM NaCl, 5.4 mM
KCl, 0.52 mM NaH2PO4, 20 mM HEPES, 11.1 mM
glucose, 3.5 mM MgCl2, 20 mM Taurine, 10 mM
Creatine; pH 7.4). LV tissue was processed, embed-
ded in paraffin and sectioned. Slides were stained for
1 h in picrosirius red solution containing 0.1% (w/v)
direct red 80 dye in a saturated aqueous solution of
1.3% picric acid. Five random sections per heart
(5 μm sections with a distance of 200 μm between sections),
and 5 areas of interest per section were photographed
at 10× magnification using non-polarised light with a
Leica DM LB2 microscope and a Leica DFC 320 camera
(Leica Microsystems, Germany). Quantification of picro-
sirius red staining used ImageProPlus software (version
5.0; MediaCybernetics), with stained area expressed as a
percentage of the total area of interest. Values were
averaged to give one representative value per heart.
For calculation of threshold, the intensity of signal for
background was set using unstained area of tissue.
Statistical analysis
Values are presented as mean ± S.E.M. from at least
three independent experiments. Statistical significances
between groups were determined by the use of Student’s
t-test or one-way ANOVA tests followed by post hoc
Tukey’s tests. Values were considered significant if p < 0.05.
Where representative immunoblots or immunocyto-
chemistry images were shown, similar data were obtained
n ≥ 3 times.
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